Clinical Trials

To view the clinical trials Valley currently has available, please use the search field or select a clinical specialty from the drop-down list below. Be sure to check back frequently, as we are always adding new studies.

For more information about any of our clinical trials, please email [email protected] or call 201-447-8453. (For cancer clinical trials, please call 201-634-5792.)

Learn more about research and clinical trials at Valley.

Clear All

A081105

Randomized Study of Erlotinib vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)

Principal Investigator(s):

  • Jason W. Suh, MD

A081801 Alchemist

Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO

Principal Investigator(s):

  • Jason W. Suh, MD

A151216

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

Principal Investigator(s):

  • Jason W. Suh, MD

AB154CSP0002 – Arcus

A Phase 2 Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination With AB122, and AB154 in Combination With AB122 and AB928 in Front-Line, Non-Small Cell Lung Cancer

Principal Investigator(s):

  • Eli Kirshner, MD

E4512 ALCHEMIST

A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

Principal Investigator(s):

  • Jason W. Suh, MD

EA5142 ANVIL

Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) - A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers

Principal Investigator(s):

  • Jason W. Suh, MD

EA5161

Randomized Phase II Clinical Trial of Cisplatin/Carboplatin and Etoposide (CE) Alone or in Combination With Nivolumab as Frontline Therapy for Extensive Stage Small Cell Lung Cancer (ED-SCLC)

Principal Investigator(s):

  • Eli Kirshner, MD

EA5182

Randomized Phase III Study of Combination AZD9291 (Osimertinib) and Bevacizumab Versus AZD9291 (Osimertinib) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)

Principal Investigator(s):

  • Eli Kirshner, MD

I-ELCAP

International Early Lung Cancer Action Program

Principal Investigator(s):

  • Robert J. Korst, MD

IELCART

Initiative for Early Lung Cancer Research on Treatment (IELCART)

Principal Investigator(s):

  • Robert J. Korst, MD